Jagsonpal Pharmaceuticals Limited — Quarter and year ended 31 March 2026
| Sr. No. | Particulars | Quarter Ended | Year Ended |
|---|---|---|---|
| 31 March (Audited) 2026 | 31 December (Unaudited) 2025 | ||
| 1 | INCOME | ||
| 1 | Revenue from operations | 642.03 | 729.45 |
| 2 | Other income | 31.68 | 29.75 |
| 3 | Total income (1+2) | 673.71 | 759.20 |
| 4 | EXPENSES | ||
| a) | Cost of materials consumed | 29.87 | 39.51 |
| b) | Purchases of stock-in-trade | 198.88 | 228.13 |
| c) | Changes in inventories of finished goods, stock-in-trade and work-in-progress | 8.92 | (3.11) |
| d) | Employee benefits expense | 155.45 | 175.79 |
| e) | Finance costs | 2.52 | 2.57 |
| f) | Depreciation and amortisation expense | 23.19 | 23.85 |
| g) | Other expenses | 137.32 | 126.45 |
| 5 | Total expenses | 556.15 | 593.20 |
| 5 | Profit before exceptional items and tax (3-4) | 117.56 | 166.00 |
| 6 | Exceptional items (net) (Refer note 4) | – | (20.79) |
| 7 | Profit before tax (5+6) | 117.56 | 145.21 |
| 8 | Tax expense: | ||
| Current tax (including earlier years) | 24.60 | 37.49 | |
| Deferred tax charge/(credit) | 5.34 | (1.79) | |
| 9 | Net profit for the period/year (7-8) | 87.62 | 109.51 |
| 10 | Other comprehensive Income (OCI) | ||
| i) | a) Items that will not be reclassified to profit or loss | 1.47 | 0.35 |
| b) Income tax relating to items that will not be reclassified to profit or loss | (0.37) | (0.08) | |
| ii) | a) Items that will be reclassified to profit or loss | – | – |
| b) Income tax relating to items that will be reclassified to profit or loss | – | – | |
| 11 | Total comprehensive income for the period/year (9+10) | 88.72 | 109.78 |
| 12 | Earnings per share (not annualised for the quarters) (Refer note 6) | ||
| Basic (Rs.) | 1.25 | 1.67 | |
| Diluted (Rs.) | 1.21 | 1.65 | |
| 13 | Paid-up equity share capital (face value per share Rs. 2) (Refer note 6) | 133.93 | 133.57 |
| 14 | Reserves excluding revaluation reserves (other equity) |
| Sr. No. | Particulars | As at 31 March (Audited) 2026 | As at 31 March (Audited) 2025 |
|---|---|---|---|
| A | ASSETS | ||
| 1 | Non-current assets | ||
| Property, plant and equipment | 5.74 | 6.11 | |
| Right of use assets | 67.76 | 82.26 | |
| Goodwill | 96.93 | 96.93 | |
| Other intangible assets | 682.67 | 759.24 | |
| Financial assets | |||
| Other financial assets | 851.11 | 173.91 | |
| Income-tax assets (net) | 0.66 | 7.98 | |
| Other non-current assets | 31.01 | 44.23 | |
| Total non-current assets | 1,735.88 | 1,170.66 | |
| 2 | Current assets | ||
| Inventories | 146.43 | 152.00 | |
| Financial assets | |||
| Trade receivables | 171.91 | 131.76 | |
| Cash and cash equivalents | 100.42 | 110.28 | |
| Bank balances other than cash and equivalents above | 960.78 | 1,177.04 | |
| Other financial assets | 0.65 | 0.67 | |
| Other current assets | 50.70 | 40.19 | |
| Total current assets | 1,430.89 | 1,611.94 | |
| Total assets | 3,166.77 | 2,782.60 | |
| B | EQUITY AND LIABILITIES | ||
| 1 | Equity | ||
| Equity share capital | 133.93 | 132.80 | |
| Other equity | 2,627.79 | 2,266.70 | |
| Total equity | 2,761.72 | 2,399.50 | |
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Financial liabilities | |||
| Lease liabilities | 65.89 | 76.32 | |
| Other financial liabilities | – | 6.66 | |
| Provisions | 11.77 | 10.38 | |
| Deferred tax liabilities (net) | 44.41 | 30.70 | |
| Total non-current liabilities | 122.07 | 124.06 | |
| Current liabilities | |||
| Financial liabilities | |||
| Lease liabilities | 15.76 | 16.07 | |
| Trade payables | |||
| Total outstanding dues of micro enterprises and small enterprises | 23.87 | 14.71 | |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 91.94 | 82.63 | |
| Other financial liabilities | 107.36 | 103.49 | |
| Other current liabilities | 25.24 | 32.00 | |
| Provisions | 13.24 | 10.14 | |
| Current tax liabilities (net) | 5.57 | – | |
| Total current liabilities | 282.98 | 259.04 | |
| Total equity and liabilities | 3,166.77 | 2,782.60 |
| Particulars | Year Ended 31 March 2026 (Audited) | Year Ended 31 March 2025 (Audited) |
|---|---|---|
| A. Cash flows from operating activities | ||
| Profit before tax | 575.18 | 698.59 |
| Adjustments: | ||
| Depreciation and amortisation expense | 94.44 | 81.31 |
| Exceptional items (Refer note 4) | 20.79 | (196.87) |
| Interest income | (117.43) | (76.45) |
| Finance costs | 10.28 | 9.58 |
| Share based payment expense | 28.05 | 68.04 |
| Excess provisions written back | (0.56) | (2.97) |
| Provision for inventory obsolescence | 0.29 | (2.04) |
| Operating cash flows before working capital changes | 35.86 | (119.40) |
| 611.04 | 579.19 | |
| Movement in working capital: | ||
| Trade receivables | (40.15) | (22.25) |
| Other current and non-current assets | (8.23) | 7.65 |
| Inventories | 5.28 | 0.01 |
| Other current and non-current financial assets | (0.53) | (2.03) |
| Trade payables | 18.47 | 21.38 |
| Other current financial and non-financial liabilities | 1.72 | 44.79 |
| Provisions | (0.50) | 3.82 |
| Cash flows from operations | 587.10 | 632.56 |
| Income-tax paid (net of refund) | (118.98) | (81.43) |
| Net cash flows from operating activities (A) | 468.12 | 551.13 |
| B. Cash flows from investing activities | ||
| Purchase of property, plant and equipment | (1.48) | (3.48) |
| Proceeds from sale of property, plant and equipment (Refer note 4(d)) | – | 357.18 |
| Cash incurred for business acquisition (net of liabilities and deferred consideration) (Refer note 4(b) and (c)) | (12.00) | (936.57) |
| Investment in bank deposits | (1,984.02) | (2,556.34) |
| Proceeds from maturity of bank deposits | 1,539.64 | 2,609.34 |
| Interest received | 101.37 | 78.40 |
| Net cash used in investing activities (B) | (356.49) | (451.47) |
| C. Cash flows from financing activities | ||
| Proceeds from issue of equity share capital (including securities premium) | 66.29 | 33.91 |
| Finance costs paid | (0.67) | (1.00) |
| Payment for principal portion of lease liabilities | (12.21) | (9.02) |
| Payment for interest portion of lease liabilities | (8.32) | (8.58) |
| Dividend paid | (166.58) | (132.29) |
| Net cash used in financing activities (C) | (121.49) | (116.98) |
| Net decrease in cash and cash equivalents (A+B+C) | (9.86) | (17.32) |
| Add: Cash and cash equivalents at the beginning of the year | 110.28 | 127.60 |
| Cash and cash equivalents at the end of the year | 100.42 | 110.28 |
| Particulars | 31 March 2026 | 31 March 2025 |
|---|---|---|
| Balance with banks in current accounts | 100.42 | 87.60 |
| Bank deposits with original maturity of less than three months | – | 22.68 |
| Cash and cash equivalents at the end of the year | 100.42 | 110.28 |
| The Department of Corporate Services – Listing | The Department of Corporate Services – Listing |
|---|---|
| BSE Ltd, | National Stock Exchange of India Ltd |
| Phiroze Jeejeebhoy Towers, | Exchange Plaza, C-1, Block G, |
| Dalal Street | Bandra Kurla Complex, |
| Mumbai-400 001 | Bandra (E) Mumbai – 400 051 |
| Scrip Code: 507789 | Symbol: JAGSNPHARM |